Enalapril Can Prevent Vascular Amplifier Development in Spontaneously Hypertensive Rats

• Published in: Hypertension (Dallas, Tex. 1979) Tex. 1979), 1990-09, Vol.16 (3), p.252-260
• Main Authors: Adams, Michael A, Bobik, Alexander, Komer, Paul I
• Format: Article
• Language: English
• Subjects: Animals; Antihypertensive agents; Biological and medical sciences; Blood Pressure - drug effects; Body Weight - drug effects; Cardiovascular system; Dose-Response Relationship, Drug; Enalapril - pharmacology; Hypertension - physiopathology; Male; Medical sciences; Organ Size - drug effects; Pharmacology. Drug treatments; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Sympathetic Nervous System - drug effects; Sympathetic Nervous System - physiology; Vascular Resistance - drug effects
• ISSN: 0194-911X; 1524-4563
• DOI: 10.1161/01.HYP.16.3.252

Three groups of spontaneously hypertensive rats (SHR) were given enalapril (25 mg/kg/day) from 4 to 9 weeks, 4 to 14 weeks, and 14 to 20 weeks of age. The drug was stopped and observations continued for another 16–21 weeks. At selected times, we measured blood pressure, in vitro hindquarter vascular resistance properties, left ventricular weight/body weight ratio, and skeletal muscle vessel norepinephrine kinetics in treated and untreated SHR and in Wistar-Kyoto (WKY) rats. At the end of each treatment period, all cardiovascular variables were close to values of WKY rats and well below those of untreated SHR, and the norepinephrine or fractional rate constant was about 25% below those levels. After enalapril was stopped, blood pressure and left ventricular weight/body weight ratio increased in parallel to levels ranging from 30% to 50% of the normal difference between untreated SHR and WKY rats. However, in SHR treated from 4 to 9 weeks and from 4 to 14 weeks of age, hindquarter resistance properties remained close to WKY rat levels for the entire observation period of 16–21 weeks after treatment, suggesting suppression of the enhanced resistance responses of SHR (amplifier properties). In SHR treated from 14 to 20 weeks of age, suppression of amplifier properties was more transient, and they redeveloped partially 5–6 weeks after cessation of therapy. When enalapril was given up to 14 weeks of age, the long-term suppression of amplifier properties was probably mainly through prevention of smooth muscle hypertrophy in resistance vessels and possibly through other mechanisms (eg., “rarefaction”). After that age, its therapeutic action was similar to that of other antihypertenslve drugs where, after drug withdrawal, there is a slow pressure rise in parallel with redevelopment of vascular and cardiac hypertrophy.